.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,255,878

« Back to Dashboard

Details for Patent: 7,255,878

Title:Stable benzimidazole formulation
Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage is no longer acidic.
Inventor(s): Lahav, legal representative; Erica (Quiriat Bialik, IL), Azoulay; Valerie (Pardes Hannah, IL), Lahav, deceased; Raffael (Quiriat Bialik, IL)
Assignee: Dexcel Ltd. (Hadera, IL)
Filing Date:Jun 21, 2000
Application Number:10/018,992
Claims:1. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of: forming a substrate with the benzimidazole derivative; preparing a solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate; neutralizing said solution by addition of an alkalizing material comprising a material selected from the group consisting of an inorganic or organic alkaline compound; and applying a single layer of said neutralized solution directly to said substrate, without an intermediate layer between said substrate and said enteric coating.

2. The method of claim 1, wherein said neutralized solution is at least about 60% neutralized.

3. The method of claim 2, wherein said neutralized solution is at least about 80% neutralized.

4. The method of claim 3, wherein said neutralized solution is at least about 95% neutralized.

5. The method of claim 1, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

6. The method of claim 1, wherein said substrate is formed by direct compression.

7. The method of claim 1, wherein said substrate is formed by wet granulation.

8. The method of claim 1, wherein said substrate is formed by coating on an inert core.

9. The method of claim 1, wherein said coating comprises spraying.

10. The method of claim 1, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40.degree. C.

11. The method of claim 1, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.

12. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of: forming a substrate with the benzimidazole derivative; preparing an aqueous solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate; neutralizing said solution by addition of an alkalizing material comprising a material selected from the group consisting of sodium, potassium or ammonium hydroxide; spraying a single layer of said neutralized solution directly over said substrate, without an intermediate layer between said substrate and said enteric coating.

13. The method of claim 12, wherein said neutralized solution is at least about 60% neutralized.

14. The method of claim 13, wherein said neutralized solution is at least about 80% neutralized.

15. The method of claim 14, wherein said neutralized solution is at least about 95% neutralized.

16. The method of claim 12, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

17. The method of claim 12, wherein said substrate is formed by direct compression.

18. The method of claim 12, wherein said substrate is formed by wet granulation.

19. The method of claim 12, wherein said substrate is formed by coating on an inert core.

20. The method of claim 12, wherein said coating comprises spraying.

21. The method of claim 12, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40.degree. C.

22. The method of claim 12, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.

23. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of; forming a substrate with the benzimidazole derivative; preparing an aqueous solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate; neutralizing said solution by addition of an alkalizing material comprising at least ammonium hydroxide; adding a plasticizer to said solution before or after said neutralizing; and directly coating said substrate with a single layer of said neutralized solution, without an intermediate layer between said substrate and said enteric coating.

24. The method of claim 23, wherein said neutralized solution is at least about 60% neutralized.

25. The method of claim 23, wherein said neutralized solution is at least about 80% neutralized.

26. The method of claim 25, wherein said neutralized solution is at least about 95% neutralized.

27. The method of claim 23, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

28. The method of claim 23, wherein said substrate is formed by direct compression.

29. The method of claim 23, wherein said substrate is formed by wet granulation.

30. The method of claim 23, wherein said substrate is formed by coating on an inert core.

31. The method of claim 23, wherein said coating comprises spraying.

32. The method of claim 23, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40.degree. C.

33. The method of claim 23, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc